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Summary: The creatinine assay, performed on Reflotron® "dry chemistry" analysers in six offices of general
practitioners, was evaluated as part of a project on the quality of laboratory determinations in decentralized
situations. The method itself was evaluated before this investigation was started. Differences were noticed
between Reflotron® machines, batches of strips, and various types of sample, viz. heparin-treated blood or
plasma gave higher results than serum or EDTA-treated samples. All Reflotron® results were lower in
comparison with wet chemistry methods. The "dry chemistry" technique was not influenced by the presence
of glucose or bilirubin (below 170 μηιοΐ/ΐ); haemoglobin interfered. By simultaneous sampling, all creatinine
determinations performed on whole EDTA blood in the general practitioners offices were repeated on serum
in centralized laboratories using "wet chemistry" techniques. In this comparison 3% of all creatinine deter-
minations in general practitioners offices were outside the 95% confidence interval. We conclude that the
creatinine determination on the Reflotron® may be used in general practitioners office testing as long as the
general practitioner is aware of its limitations and can rely on a "reference" laboratory for training, quality
control and repetition of unexpected results.
Introduction «- · * · ^ ™ ^ ι Λ \\Ί Λoffices in two areas in the Netherlands. We compared
The creatinine assay on the Reflotron® "dry chem- the decentralized Reflotron® creatinine values with
istry" analyser is based on an enzymatic breakdown the results of Reflotron® determinations performed
of creatinine followed by measurement of the liberated by laboratory technicians using "wet chemistry"
hydrogen peroxide (1). The reagents are applied in a measurements in two centralized ("reference") hos-
dry form on a solid matrix. This so-called "dry chem- pital laboratories, and with the results of a reference
istry" reagent system is also intended for use in de- method for creatinine determination (based on the
centralized testing, thus enabling a general practi- Fuller^ earth technique) (2, 3). In one of the central
tioner to perform determinations in his/her office. The laboratories we performed all other tests associated
study described here is part of a greater evaluation of with the evaluation of the performances of the cre-
the influence of the introduction of facilities for chem- atinine determination on the Reflotron®.
ical and simple haematological determinations on
general medical practice. This article reflects the per-
formance of the creatinine determination only, with
special emphasis on the use of the method by non- Matenals and Methods
laboratory skilled personnel. For this purpose we Project setup
placed Reflotron® systems in general practitioners The project was carried out in two regions of the Netherlands,
around the cities of Amsterdam (A) and Leeuwarden (L). The
participants were six general practices and two central labora-
') Subsidized by Ziekenfondsraad, Postbus 396,1180 BD Am- lories in the aforementioned cities, which served the general
stelveen, The Netherlands
 ; practitioners in their region. The distance between central lab-
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oratory and general practice was never more than 50 km. For
more than 12 months the general practitioners used a Reflo-
tron« 74F "dry chemistry" analyser (Boehringer Mannheim,
Germany) and a CBC-5 haematology analyser (Coulter Elec-
tronics, Mijdrecht, The Netherlands), both connected to an
Olivetti M250 computer (Olivetti, Leyden, The Netherlands).
Identical analytical systems were installed in each central lab-
oratory. The Reflotron·8* was used for the measurement of
creatinine as one of the chemistry determinations performed by
the general practitioners or his/her assistant; the relevant hae-
matological quantities were determined on the CBC-5. The
computer was used for a number fo purposes: for communi-
cation with the central laboratory, to collect all data of deter-
minations on Reflotron® and CBC-5, and to control their
quality. This latter aspect was assured by the software built in
the computer, since, before Reflotron® or CBC-5 could be used
for measurement of a specific test in patient samples, a control
serum or blood had to be analysed. Only when this result fell
within predefined limits, was the apparatus released for 24 hours
for that test. Moreover, in the laboratory of the University
Hospital of Amsterdam two extra Reflotron® instruments (Re-
flotron® 1 and 2) were used for test purposes.
Creatinine methods and reagents
Creatinine in the central laboratories was determined on a
SMAC (Technicon, USA) (Amsterdam) and a Hitachi 717
(Boehringer Mannheim, Germany) (Leeuwarden) analyser, re-
spectively. On both instruments reagents of their respective
manufacturers were used. As a reference method for creatinine
the technique with Fuller's earth was used. On the Reflotrons®
we used one lot number of Reflotron® creatinine reagent car-
riers with creatininase (Boehringer Mannheim product number
886874): 23462741; for checking differences between lots we
used a second batch with lot number 23463232.
Centralized laboratories
Agreement between the results of the wet chemistry analysers
in the two "reference" laboratories was checked with patient
samples that were exchanged between the two locations. One
location (Amsterdam) used heparin plasma, while the other
(Leeuwarden) used serum in its normal routine setting. To
compare results from both locations, three batches (each con-
sisting of 30 heparin samples from Amsterdam and 10 serum
samples from Leeuwarden) of normal routine samples were
dispatched immediately after analysis to the other laboratory
to be analysed directly after arrival. This was done on three
separate days within a period of seven weeks. One sample
(heparin) was of insufficient quantity and was omitted from
the calculations. In total 119 samples were compared.
Blood samples
EDTA, serum and heparin samples were taken by venipuncture
using evacuated blood collecting tubes (Venoject, Terumo Eu-
rope N. V., Leuven, Belgium). In the general practices blood
samples were drawn from outpatients: EDTA blood for the in-
office Reflotron® and CBC-5 determinations, and serum for
the determinations in the two "reference" laboratories. All
analyses in the general practitioners ofifices were performed
with EDTA blood immediately after the samples were collected;
the serum samples, collected at the same time, were sent as
soon as possible to the "reference" laboratory in the region for
comparison with the "wet chemistry" method for creatinine.
Samples for the Reflotron® performance studies in one of the
central laboratories (Amsterdam) were obtained from hospital
patients and laboratory personnel (EDTA and heparin sam-
ples).
Controls
For quality control of the creatinine determinations in the
laboratories and in the general practitioners offices we used
several batches of precinprm U (analysed) control serum from
Boehringer Mannheim, especially niade for use on the Reflo-
tron®. In the software of the computer, used for the 24 hour
release of the Reflotron®, we applied the control limits as
provided by the manufacturer.
Interfering substances
To evaluate the influence of some substances known to interfere
with the creatinine determination, we mixed heparin plasma
samples containing known high and low concentrations of
glucose, bilirubin or haemoglobin, so as to obtain a full con-
centration range of each interfering component. Creatinine
concentrations were then determined on the laboratory Reflo-
tron® 1, the SMAC and with the Fuller's earth method.
Statistical methods
For comparison of the creatinine results we evaluated the re-
sulting data, following the statistical recommendation of Pass-
ing & Bablok (4, 5). For this purpose we used a software package
called "EVAL-KIT" (6). For the interpretation of the results
of the regression equations and the statistics on patient sample
data we used the EP9-P guideline (7); outliers in the patient
sample data of table le were determined as described in this
guideline. The difference plot was created as described by Pol-
lock et al. (8).
Results
Comparison of central laboratories
At the start of this study it was essential to have an
insight into possible differences between the creatinine
results of the two central laboratories. Table la shows
the correlation data of the 119 samples. Based on the
confidence interval (p < 0.05) for slope and intercept,
1800
300 600 900 1200 1500
Creatinine SMAC (serum + plasma)
1800
Fig. 1. Scatter plot and regression line of creatinine determi-
nations in plasma and serum samples at the "reference"
laboratories.
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the means for the serum samples are not significantly
different and the means for the plasma samples are
significantly different. Figure 1 shows the scatter plot
and the regression line for all serum and plasma
samples.
Differences between machines
We performed a series of replicate creatinine assays
with EDTA plasma and blood on the Reflotrons® 1
and 2 in the central laboratory to check differences
between the machines and specimens (tab. 2a). The
EDTA plasmas were prepared from EDTA blood by
centrifugation. It is noted that differences between
two machines do exist, that EDTA blood gives higher
results than its corresponding plasma, and that the
coefficients of variation of the blood determinations
are higher than those of the plasma measurements.
0 30 60 90
Creatinine (botch 23463232} [μηιο|/Ι]
120 160
Fig. 2. Comparison of batches of creatinine reagent using the
Reflotron®.
Tab. 2. Machine characteristics as exemplified by
(a) replicate assays of patient samples on two instru-
ments, and
(b) between day coefficient of variation with control
sera.
a) Imprecision within run (patient samples)
Sample material Reflotron® 1
Mean SD CV Ν
EDTA-plasma 1
EDTA-blood 1
EDTA-plasma 2
EDTA-blood 2
Sample material
EDTA-plasma 1
EDTA-blood 1
EDTA-plasma 2
EDTA-blood 2
80.9
86.3
77.3
78.1
2.7
6.8
2.9
5.5
3.3
7.9
3.8
7.1
15
15
15
15
Reflotron® 2
Mean
81.8
95.4
78.0
88.2
SD
2.7
11.0
2.0
9.0
CV
3.3
11.6
2.6
10.5
Ν
15
15
15
15
b) Imprecision between days (control sera)
Control serum Mean SD CV Ν
Lotnr. 161171
Lotnr. 166507
212.8
247.8
9.53
7.43
4.48
3.00
47
48
Reproducibility
Reproducibility was checked on the Reflotron® 1 with
two lots of Precinorm U control serum. Analyses were
done three times a day during 16 days, and the results
as shown in table 2b demonstrate a coefficient of
variation of 3% and 4.5%.
Different batches of strips
Batch to batch comparison was done on the Reflo-
tron® 1, using 41 heparin plasma patient samples and
the two batches of strips. The results are shown in
table Ib and figure 2. Based on the confidence interval
(p < 0.05) for slope and intercept the batches are not
different. Based on the Student's test the means of the
patient samples tested with the two batches are dif-
ferent (p < 0.01).
Different sample materials
The results of comparison of several sample materials
used with different methods in shown in table Ic.
Reflotron® experiments were done with the Reflo-
tron® 1 from the previous tests. In this experiment no
great differences were noticed between EDTA blood
and plasma (fig. 3). Heparin plasma shows higher
200
160
120
S 80
40
40 80 120 160
Creatinine (EDTA blood) [μΐτιοΐ/l]
200
Fig. 3. Comparison of EDTA blood and plasma samples using
the Reflbtron®.
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Fig. 4. Comparison of EDTA plasma and heparin plasma using
the Reflotron®. Fig.
ν
 Ο 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 6 0 0 7 0 0 8 0 0 9 0 0
Creatinine (Fullers earth) fomol/l]
6. Comparison Fuller's earth and SMAC creatinine.
250
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0
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Creatinine (Reftotron hepartn plasma)
900
800
70
°
600
500
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200
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Fig. 5. Comparison of heparin plasma on SMAC and Reflo-
tron®.
results than EDTA plasma (fig. 4). The Reflotron®
gives lower results than the SMAC using heparin
plasma (fig. 5).
Different methodologies
We compared the laboratory "wet chemistry"
(SMAC) and the Reflotron® method with the refer-
ence method for creatinine (tab. Id and figs. 6, 7, 8),
using heparin plasma. Our reference method showed
higher creatinine results.
Interferences
Glucose up to a concentration of 32 mmol/1 did not
influence either of the creatinine determinations used
0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 6 0 0 7 0 0 8 0 0 9 0 0
Creatinina (Fuller's earth) [μπχ>Ι/η
Fig. 7. Comparison Fuller's earth and Reflotron® creatinine.
Fig.
1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 6 0 0 7 0 0 8 0 0
Creatinine (SMAC) [μΓηοΙ/1]
8. Comparison SMAC and Reflotron® creatinine.
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Fig. 9. Interfering substances: glucose, bilirubin and free hae-
moglobin.
a) glucose [mraol/1], ο SMAC, α Fuller's earth, χ Re-
flotron
b) bilirubin [μπιοΙ/1], ο SMAC, α Fuller's earth, χ Re-
flotron
c) free haemoglobin [mmol/1], ο SMAC, α Fuller's
earth, χ Reflotron EDTA blood, Δ Reflotron EDTA
plasma
(fig. 9). Neither the Reflotron® creatinine method,
nor the other methods showed any interference from
bilirubin up to a concentration of 170 μιηοΐ/ΐ (fig. 9).
The Reflotron® creatinine method gave falsely ele-
vated results when the haemoglobin concentration
was above 0.05 mmol/1. With a haemoglobin concen-
tration of 0.1 mmol/1 the creatinine was raised by
50% (fig. 9); neither the Fuller's earth technique, nor
the SMAC method showed deviations from the orig-
inal creatinine value.
Determinations in general practitioners of-
fices
After having established the quality of the creatinine
determination per se on the Reflotron®, we deter-
mined the quality of the results as performed by non-
skilled personnel in doctors' offices. Table le shows
the results of the creatinine determinations in EDTA
blood performed first in a general practitioners office,
followed by an analysis in serum by one of the lab-
oratories. The results are given for all samples deter-
mined in the period of one year. The scattergram of
the sample data and the difference plot are represented
in figure 10. Using the EP9-P guideline we found 7
outliers (marked with black squares in the scatterplot
and black dots in the difference plot in fig. 10) in the
set of 251 sample data. In all these 7 cases the general
practitioners found the data in conflict with this ex-
pectation of the creatinine value and asked for the
"reference" laboratory result.
800
Ό 100 200 300 400 500 βΟΟ 700 800
Creatinine (serum, laboratory) [μπκ>|/1]
6000 200 400
Creatinine (mean 0.5(x+y))
1
 Fig. 10. Scattergram and difference plot of creatinine results
from general practitioners (GP) and "reference" lab-
oratory. . f
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Discussion
As already stated the evaluation of the determination
of creatinine on the Reflotron® is part of a greater
study concerning the quality of tests in doctor's of-
fices. All determinations performed by general prac-
titioners were repeated as soon as possible in two
hospital laboratories designated as "reference" labo-
ratories. Although the general practitioners used
EDTA-blood, since one sample then would be suffi-
cient for both "dry chemistry" and haematology test-
ing, we choose to exchange serum samples between
the general practitioners offices and the laboratories.
At the start of this study we had to be sure that no
significant differences existed between the two "ref-
erence" laboratories. As table la and figure 1 show,
there are small but irrelevant differences between the
two laboratories using different methodologies for the
creatinine determination: in the set of 119 data pairs
we detected one outlier. Based on the linear regression
equation, the difference between the laboratory values
at a concentration of 140 μηιοΐ/ΐ is 1.4 μπιοΐ/ΐ. This
concentration was chosen since it is the cut-off value
used by the general practitioners in their daily prac-
tices as the trigger value for further action: the de-
tected difference has no relevance for medical decision
making.
The difference found between plasma and serum sam-
ples can possibly be explained by the effect of heparin
plasma samples on the kinetic Jaffe reaction used on
the Hitachi. Using EDTA plasma, the two different
Reflotron® 74F machines gave the same results for
mean and standard deviation. When EDTA blood
samples were used, differences in the mean and stan-
dard deviation were found (tab. 2a); since the two
machines were used in parallel for the determinations
with the same samples there can be no effect of sample
storage. We have no explanation for these differences,
but we note that Blijenberg (9) also found an instru-
ment variation and questioned the instruments' cali-
bration.
The results obtained for the control sera (tab. 2b) fall
within the range reported by the manufacturer. The
coefficients of variation are in the same range
(3^4.5%) as those found for plasma samples in the
previous experiment. When whole blood is used, the
coefficient of variation increases to 7.2—11.6% (tab.
2a). Blijenberg (9) reported coefficients of variation
of the same magnitude. A possible explanation for
the increase in coefficients of variation is the influence
of variable haematocrit values on the effective sample
volume.
Table Ib gives a comparison of two batches of Reflo-
tron® creatinine reagent strips for heparin plasma
samples. According to the confidence intervals, slope
and intercept of the regression equation do not differ
significantly from 1.00 and 0.0, respectively (7). The
squared coefficient of correlation (0.854) shows that
for > 85% of the data the y-value can be calculated
from the x-value, using the regression equation. There
is a significant difference in mean creatinine results,
indicating that the calibration from batch to batch is
disputable. Since this is a closed system with no fa-
cility for changing the instrument calibration, this
must be seen as a drawback (9).
Table Ic shows that the means for 111 EDTA plasma
and blood samples are not significantly different (fig.
3). The differences as reported in table 2a are not seen
in this experiment; our impression is that the sample
size plays an important role in this effect. On the
Reflotron® heparin plasma samples differ from the
EDTA samples from the same person (fig. 4). We
have no explanation for these differences, but it is
probable that EDTA influences the reagent system
used in the strips; on the SMAC we never found
differences between heparin plasma and EDTA
plasma. In its most recent instructions Boehringer
advises that heparin plasma or serum be used on the
Reflotroii® for the creatinine determination. The ad-
vantage is a lower coefficient of variation, but this
approach is much less practicable for office testing.
In general, there is a large difference between EDTA
samples and heparin samples (tab Ic). From all cor-
relation coefficients it can be seen that the data ranges
are not sufficiently extended: all samples were chosen
from patients without kidney malfunction. In table
Id and figures 6 and 7 we compare the Fuller's earth
method using heparin plasma samples with the Reflo-
tron® and the SMAC. The Fuller's earth method gives
significantly higher results than SMAC and Reflo-
tron®. SMAC gives significantly higher results than
the Reflotron®. Based on the correlation coefficients
(tab. Id) the data for the different methods correlate
very well. A possible explanation for the higher results
of the reference method may be found in the article
of Kanturek et al. They showed that Lloyd's reagent
(Fuller's earth) absorbs several Jaffe reacting agents
(10).
Comparison between the results of the general prac-
titioners and the "reference" laboratories shows that
the overall sample set contains 7 outliers in 251 sam-
ples (fig. 10). After rejection of outliers the data range
is not yet acceptable (r = 0.950). The regression data
show a constant bias in this set of — 1.07 μιηοΐ/ΐ and
a proportional bias of —8.5%. At a cut off concen-
tration of 140 μηιοΐ/ΐ the Reflotron® value would be
119.6 μπιοΐ/ΐ (based on lineair regression). As we
Bur. J. Clin. Chem. Clin. Biochein, / Vol. 31
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demonstrated (fig. 9), interference by haemoglobin,
even at a low concentration, may be responsible for
the outliers. When working with whole blood samples
haemolysis is not noticed, and haemoglobin concen-
tration that are too low to be noticed with the naked
eye in plasma or serum are quite able to influence the
results. Interference by glucose and bilirubin was
found to be negligible under normal circumstances.
The difference plot shows a large scatter at values
around 100 μπιοΐ/ΐ and suggests a concentration-re-
lated difference.
Although the creatinine test on the Reflotron® gives
biased results it may be applicable in the general
practitioners office as long as the general practitioner
is aware of its limitation. He should have a good
communication with a "reference" laboratory for the
necessary training, quality assurance and repetition
of unexpected results (11). The general practitioner is
in general very capable of distinguishing normal re-
sults from outliers. Thus, in our experiment we let the
general practitioners predict the results of the deter-
minations performed in their respective offices. In the
case of outliers the prediction was nearly always in
agreement with the result of the "reference" labora-
tory. The advice of the manufacturer to use serum or
plasma severely limits the use of the creatinine test
on the Reflotron® in general practitioners offices. The
necessity for an extra centrifugation step diminishes
its use in direct patient care and requires the invest-
ment in an expensive laboratory centrifuge. Although
we are aware of the drawbacks (12), the general prac-
titioners interested in signs of kidney malfunction
might use the determination of urea on the Reflo-
tron®, since this assay can be performed with whole
blood.
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